Sugi Predict

Sugi Predict / Compounds / SCHEMBL8008730

SCHEMBL8008730

SCHEMBL8008730

CN1CCC2(CC1)CNC(=O)C2

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 1/20 0.48
▸ CYP11B2 P19099 1/20 0.48
▸ OPRM1 P35372 1/20 0.45
▸ OPRL1 P41146 1/20 0.45
▸ NEK2 P51955 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ LRRK2 Q5S007 2/20 0.40
▸ PDCD1LG2 Q9BQ51 1/20 0.36
▸ CD274 Q9NZQ7 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ PRMT1 Q99873 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16565923 0.89 CYP11B1 (0.46) CYP11B1CYP11B2OPRM1OPRL1NEK2
SCHEMBL19534273 0.82 NEK2 (0.42) CYP11B1CYP11B2NEK2SMN1; SMN2CHRM2
SCHEMBL14728480 0.81 NEK2 (0.47) NEK2CHRM2CHRM3TSHR
SCHEMBL10263814 0.80 CYP11B1 (0.46) CYP11B1CYP11B2OPRM1OPRL1SMN1; SMN2
SCHEMBL16190003 0.80 — —
SCHEMBL18123519 0.80 CYP11B1 (0.44) CYP11B1CYP11B2OPRM1OPRL1SMN1; SMN2
SCHEMBL18123338 0.80 CYP11B1 (0.44) CYP11B1CYP11B2OPRM1OPRL1SMN1; SMN2
SCHEMBL17517003 0.79 CYP11B1 (0.45) CYP11B1CYP11B2OPRM1OPRL1SMN1; SMN2
SCHEMBL10200639 0.79 CYP11B1 (0.45) CYP11B1CYP11B2OPRM1OPRL1SMN1; SMN2
SCHEMBL10262954 0.79 CYP11B1 (0.48) CYP11B1CYP11B2OPRM1OPRL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066027-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2024-02-29 — — US disclosed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 — — US disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
US-20230133671-A1 SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES Epizyme, Inc. (US) 2023-05-04 — — US disclosed
US-20230049113-A1 METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 Epizyme, Inc. 2023-02-16 — — US disclosed
WO-2022258622-A1 COMBINATION TREATMENT OF CANCER ARES TRADING S.A. (CH) 2022-12-15 — — WO disclosed
EP-3661941-B1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP disclosed
EP-3172214-B1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2020-05-13 — — EP disclosed
US-10428088-B2 Muscarinic receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-10-01 — — US disclosed
EP-3041841-B1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2019-06-05 — — EP disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 — — US disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 — — US disclosed
US-7977349-B2 Substituted quinolones III AICURIS GMBH & CO. KG (DE) 2011-07-12 — — US disclosed
US-7977349-B2 Substituted quinolones III AICURIS GMBH & CO. KG (DE) 2011-07-12 — — US disclosed
EP-1994020-B1 Substituted quinolones III AICURIS GMBH & CO KG (DE) 2011-06-22 — — EP disclosed
US-20090181996-A1 SUBSTITUTED QUINOLONES III BAYER HEALTHCARE AG (DE) 2009-07-16 — — US disclosed
US-20090181996-A1 SUBSTITUTED QUINOLONES III BAYER HEALTHCARE AG (DE) 2009-07-16 — — US disclosed
WO-2009053716-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2007090579-A2 SUBSTITUTED QUINOLONES III AICURIS GMBH & CO. KG (DE) 2007-08-16 — — WO disclosed
WO-2000027790-A1 MUTILIN COMPOUNDS SMITHKLINE BEECHAM P.L.C. (GB) 2000-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428088-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 CYP11B1 612/4885CYP11B2 634/4885OPRM1 34/4885
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS PIK3CA, PIK3CD, PI4KA CYP11B1 911/4885CYP11B2 1568/4885OPRM1 2314/4885
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND AR, GPER1, CRBN CYP11B1 84/4885CYP11B2 195/4885OPRM1 322/4885
US-20090181996-A1 SUBSTITUTED QUINOLONES III IRF3, TPMT, TOP2A CYP11B1 1944/4885CYP11B2 1739/4885OPRM1 3454/4885
US-20230049113-A1 METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 NSD1, NSD3, EHMT1 CYP11B1 4246/4885CYP11B2 4505/4885OPRM1 4370/4885
US-20240066027-A1 NOVEL PAR-2 INHIBITORS F2RL1, F2R, F2RL3 CYP11B1 2199/4885CYP11B2 1143/4885OPRM1 1391/4885
US-20230133671-A1 SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES EZH2, HDAC2, SETD2 CYP11B1 2040/4885CYP11B2 1296/4885OPRM1 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.